Poseida Therapeutics (PSTX) Announces Publication Highlighting Potential of Cas-CLOVER™ as an Efficient and Robust Gene Editing System for Developing Allogeneic CAR-T Products

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced a peer-reviewed publication highlighting the potential of its proprietary Cas-CLOVER Site-specific Gene Editing System as a high-efficiency platform for the production of allogeneic CAR-T cells. The paper, titled "Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of TSCM-enriched allogeneic CAR-T cells," was published online today in Molecular Therapy – Nucleic Acids. The paper will appear in print in the September 2022 issue of the journal.

"We are excited to publish data from this very comprehensive study of our gene editing system in T cells," said Eric Ostertag, M.D., Ph.D., Executive Chairman of Poseida Therapeutics. "This publication validates the precision of our proprietary Cas-CLOVER system, which is utilized in the manufacture of our fully allogeneic product candidates currently in clinical trials, including P-BCMA-ALLO1 for relapsed/refractory multiple myeloma and P-MUC1C-ALLO1 for multiple solid tumor indications."

Cas-CLOVER is a novel, high-fidelity gene editing system that can be used for high-efficiency gene editing in T cells to create allogeneic CAR-T products. In these published studies, Cas-CLOVER was used for multiplexed gene editing in resting T cells, which resulted in allogeneic product candidates with a high percentage (45%-70%) of desirable T stem cell memory (Tscm) cells. Using next-generation sequencing, off-target activity was measured at a rate between 0.012% and 0.089%, which is significantly lower than many other gene editing platforms. In addition, off-target translocations, which are undesirable chromosomal abnormalities, approached the lower limit of detection at a frequency of less than 0.01%.

"Cas-CLOVER is a highly versatile and precise system that can be used to make site-specific deletions, insertions and knock-ins and works in multiple cell types," said Blair Madison, Ph.D., Vice President, Genetic Engineering at Poseida Therapeutics, first author of the publication. "We continue to innovate, including the enhancement of Cas-CLOVER, to create potentially transformative treatments for patients in oncology and rare diseases."

You May Also Be Interested In

• Inhibikase Therapeutics (IKT) Issues Letter to Shareholders and Provides Update on Development Programs
• Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
• TD SYNNEX Corp. (SNX) Announces Resignations of Robert Kalsow-Ramos and Matthew Nord from Board